Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mirela Anghelina

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12Charles F Eisenbeis, Gregory B Lesinski, Mirela Anghelina, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 VariantsPanke Qu, Julia N Faraone, John P Evans, et al.
Cell Reports. Medicine|May 6, 2023
Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariantsJulia N Faraone, Panke Qu, John P Evans, et al.
Biorxiv : the Preprint Server for Biology|October 27, 2022
Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2Panke Qu, John P Evans, Julia Faraone, et al.
Cell Host & Microbe|December 8, 2022
Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2Panke Qu, John P Evans, Julia N Faraone, et al.
Cell Reports|April 27, 2023
Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variantsPanke Qu, Julia N Faraone, John P Evans, et al.
Leukemia Research|July 23, 2022
Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemiaMirela Anghelina, Michelle J Naughton, Qiuhong Zhao, et al.
Blood|March 23, 2021
Phase 2 study of ibrutinib in classic and variant hairy cell leukemiaKerry A Rogers, Leslie A Andritsos, Lai Wei, et al.
The Journal of Clinical Investigation|March 5, 2014
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcomeHouda Alachkar, Ramasamy Santhanam, Kati Maharry, et al.
Leukemia & Lymphoma|September 7, 2022
Development of a distributed international patient data registry for hairy cell leukemiaLeslie A Andritsos, Mirela Anghelina, Jasmine Neal, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12Charles F Eisenbeis, Gregory B Lesinski, Mirela Anghelina, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 VariantsPanke Qu, Julia N Faraone, John P Evans, et al.
Cell Reports. Medicine|May 6, 2023
Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariantsJulia N Faraone, Panke Qu, John P Evans, et al.
Biorxiv : the Preprint Server for Biology|October 27, 2022
Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2Panke Qu, John P Evans, Julia Faraone, et al.
Cell Host & Microbe|December 8, 2022
Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2Panke Qu, John P Evans, Julia N Faraone, et al.
Cell Reports|April 27, 2023
Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variantsPanke Qu, Julia N Faraone, John P Evans, et al.
Leukemia Research|July 23, 2022
Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemiaMirela Anghelina, Michelle J Naughton, Qiuhong Zhao, et al.
Blood|March 23, 2021
Phase 2 study of ibrutinib in classic and variant hairy cell leukemiaKerry A Rogers, Leslie A Andritsos, Lai Wei, et al.
The Journal of Clinical Investigation|March 5, 2014
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcomeHouda Alachkar, Ramasamy Santhanam, Kati Maharry, et al.
Leukemia & Lymphoma|September 7, 2022
Development of a distributed international patient data registry for hairy cell leukemiaLeslie A Andritsos, Mirela Anghelina, Jasmine Neal, et al.
Pageof 3